# Insulin and the Politics of Drug Pricing **The concept:** Insulin is the hormone that lets cells take up glucose; people with type 1 diabetes and many with type 2 need it to live (see Carbohydrates and Blood Sugar). It was discovered in 1921 and its inventors sold the patent for one dollar so that no one would profit from a life-saving necessity. A century later, the U.S. list price of insulin had climbed into the hundreds of dollars per vial, forcing some patients to ration a drug that costs a few dollars to make. That arc — from a gift to humanity to the emblem of American drug-pricing dysfunction — makes insulin the single most legible case study in the political economy of medicine, where the biochemistry is simple and the pricing is the scandal. ## The Science and the History Biochemically, insulin is a small protein hormone (see Hormones and Endocrine Signaling). Before 1921 a type 1 diabetes diagnosis was a death sentence; Frederick Banting, Charles Best, and colleagues at the University of Toronto isolated insulin and demonstrated its life-saving effect, and Banting reportedly said insulin belonged to the world, not to him. The patent was sold for a token sum. Modern insulin is *biosynthetic* — made by inserting the human insulin gene into bacteria or yeast via recombinant DNA (see Nucleic Acids and the Central Dogma and CRISPR), so it is cheap to manufacture. Yet a small number of companies, dominated by [[Eli Lilly]], Novo Nordisk, and Sanofi, control the U.S. market, and through incremental "improvements," patent extensions, and an opaque pricing system involving pharmacy benefit managers and rebates, list prices rose far faster than inflation for decades. The drug did not get more expensive to make; the system got better at extracting. ## KB Applications ### The Cleanest Indictment of American Drug Pricing Insulin strips the standard [[Big Pharma]] pricing defense to nothing. The "we need high prices to fund risky R&D" argument (examined in Pharmacology and Drug Metabolism) cannot apply to a century-old molecule with no remaining discovery cost. What remains is pure market structure: limited competition, patent gaming on delivery devices and formulations, and a middleman system that hides who captures the markup. For a KB tracking how concentrated economic power operates, insulin is the case where the mechanism is naked — which is exactly why it became a bipartisan political flashpoint, with price caps (the $35 Medicare cap, later voluntary manufacturer caps) emerging as one of the few drug-pricing reforms able to pass. ### A Rare Cross-Ideological Pressure Point Drug pricing is one of the few issues where populist-right and progressive-left rhetoric converge, and insulin is its emblem. The Trump-era [[Most-Favored-Nation Drug Pricing Deals]] and the Biden-era Inflation Reduction Act negotiation provisions came from opposite coalitions but aimed at the same target. The KB notes both the genuine convergence and its limits: the populist right's drug-pricing anger often coexists with hostility to the public mechanisms (negotiation authority, regulatory power) that could actually deliver lower prices — a tension insulin makes concrete. ### The Contrast With Supplement Credulity Insulin also sharpens the double standard documented in The Supplement Industry. The medical-populist movement directs intense suspicion at pharmaceutical companies — sometimes warranted, as the insulin story shows — yet that same suspicion rarely extends to the unregulated wellness products it markets. Insulin is a case where the "Big Pharma is gouging you" critique is *true*; the KB's point is that a true grievance is being selectively deployed, fueling distrust of vaccines and proven medicine while sparing the supplement economy that profits from the same anti-establishment energy. ## See Also - Biochemistry — parent sub-hub - Carbohydrates and Blood Sugar — what insulin does - Pharmacology and Drug Metabolism — the R&D-cost pricing argument - [[Big Pharma]] — the industry - [[Eli Lilly]] — the dominant U.S. insulin maker - [[Most-Favored-Nation Drug Pricing Deals]] — the Trump-era pricing push